With over 100,000 new medical research articles being published each year, it has been almost impossible for even the most motivated professionals to keep up with the flood of new data on drugs and illnesses--until now.
Last year Bioinformatics start up CureHunter, Inc. began to solve the problem of "burial by data" and mixed data quality by creating the first intelligent system that could read the entire US National Library of Medicine (1949-2008 updated daily) and automatically compute the optimal medications to treat any known human disease using its proprietary Network Graph Theory algorithms operating over data from peer-reviewed journals only.
June 1, will mark the first anniversary of the online web-based system's availability to all doctors, patients, and pharmaceutical research scientists worldwide through www.curehunter.com. The date also marks the addition to the system of numerous technical enhancements aimed at speeding up drug discovery and alerting patients and physicians to the latest scientific findings on potential cures for serious illness.
Most important of the new features for doctors and patients is a unique CureHunter RSS news feed that reads approximately 2,000 new peer-reviewed only clinical and biomedical research papers per week and automatically extracts key statements from them that are "outcome centric." That is, the article must state some specific observation, technical finding, result, effect or conclusion about what medication or biological agent produced the new clinical outcome of merit.
Pharmaceutical professionals, doctors and patients can subscribe without charge to the CureHunter Rss feeds and select to track: Pharma manufacturer and specific products, all drugs with breaking news, only new scientific findings on their specific disease, news of new therapies, or all of the above.
CureHunter's high precision data extraction system keeps the information content in its feeds highly quality controlled and focused on usable results rather than general news, chat or information. The feed outputs are also quantified and weighted for clinical utility so they can be input into the main CureHunter analytic engine and become part of the machine's own memory of "what works" as originally published in close to 18 million research articles.
In this way, the CureHunter AI Discovery Engine continues to learn daily-like any good scientist--and modifies its "machine 2nd opinion" of best treatment options that is presented in seconds on every doctor's screen. The processed feed data also become part of CureHunter's Network Graph Theory models for drug discovery and automatic re-targeting and purposing of existing medications. If for example, a new biomarker is cited in the feed as correlating highly with a cancer, that data point will be retrieved and evaluated with all cancer markers when a patient or researcher is studying the specific illness or therapy for it.
Similarly, if a new medication or biological agent has been shown to achieve improved disease remission rates, that data will be captured and integrated into the system's knowledge of all medications that have shown clinical efficacy. The data will also automatically be correlated with related diseases and agents that share functional clinical properties, mechanisms of action, or pathogenic pathways.
Because the CureHunter Engine has been trained to seek "clinical effect centricity" across all diseases drugs and agents indexed since 1949, the machine can often discover relationships very quickly that historically have taken many years for human observers to realize and put to clinical use in new drug discovery or available treatments.
Through the CureHunter machine's ability to sum all we know toward clinical efficacy, the company hopes to support the FDA's Critical Path Program goals and their drive to speed up both new cure discovery and safety analyses that are now such powerful national health care priorities.
With Microsoft Windows Live Mail, Microsoft HealthVault, Internet Explorer, Safari, FireFox or other modern browsers, users can choose with a mouse click to have the particular CureHunter RSS News Feeds they wish by selecting research on their particular Medications, Disease, or Related Therapies or all three. Industry analysts can also select and track only those new outcomes achieved by specific pharmaceutical companies and even individual products.
The benefits of using the CureHunter intelligent news reader system are quite powerful, especially for patients and families hoping for breakthroughs on serious illness. A check of the morning's email might just alert them to very hopeful, promising or immediately usable new results they should discuss with their physicians.
At the same time our overworked physicians can be kept literally up to date as much as 4 months in advance of new journal research formal publication. Researchers can thoroughly evaluate prior art when preparing publications on their own preemptive work. Pharma marketers and stock analysts can also be automatically advised of competitive product and scientific advances mentioning their key meds in outcome centric papers. Health information sites and broadcasters with staff experts in medicine and pharmacy can also be kept very current by subscribing to CureHunter RSS feeds.
For more information or to start receiving new research, visit the company's web site, search a disease on the home page query field, and then select RSS feed icon at the top right hand column of the next page displayed.
URLS:
www.curehunter.com
Patients, doctors, scientists search Disease Name first on home page Rss will appear on page two with supporting information
Pharmaceutical Company and Product specific feeds: http://www.curehunter.com/public/fdaFirmSearch.do
Visual Medical Dictionary for medical and nursing students:
http://www.curehunter.com/public/dictionary.do
MOBILE PDA-Cell Phone Version:
http://www.curehunter.com/m/showTopPage.do
Partners and investors please use contact form at the site:
http://www.curehunter.com/public/contactForm.do
Corporate Background:
CureHunter is an Oregon Corporation founded in 2003, for the purpose of building an advanced artificial intelligence machine that uses massive biomedical knowledge bases to compute new cures for human disease. System access is licensed worldwide to doctors, scientists, and patients for the purposes of improving positive patient outcome rates, advancing our research knowledge, and enabling the practice of Evidence-Based Medicine in Real Clinical Time. Approximately 80,000 visitors per month ask CureHunter for its "Machine 2nd Opinion" of the optimal medication to treat specific illnesses.
The company has offices in Tokyo, Japan and Headquarters in Portland, Oregon, USA.
Contact:
CureHunter, Inc., Portland, Oregon
May 21, 2008 - 10:00 AM - PDT - USA
Judge Schonfeld, CEO - judge@curehunter.com or 503.246.6489
###
With over 100,000 new medical research articles being published each year, it has been almost impossible for even the most motivated professionals to keep up with the flood of new data on drugs and illnesses--until now.
Last year Bioinformatics start up CureHunter, Inc. began to solve the problem of "burial by data" and mixed data quality by creating the first intelligent system that could read the entire US National Library of Medicine (1949-2008 updated daily) and automatically compute the optimal medications to treat any known human disease using its proprietary Network Graph Theory algorithms operating over data from peer-reviewed journals only.
June 1, will mark the first anniversary of the online web-based system's availability to all doctors, patients, and pharmaceutical research scientists worldwide through www.curehunter.com. The date also marks the addition to the system of numerous technical enhancements aimed at speeding up drug discovery and alerting patients and physicians to the latest scientific findings on potential cures for serious illness.
Most important of the new features for doctors and patients is a unique CureHunter RSS news feed that reads approximately 2,000 new peer-reviewed only clinical and biomedical research papers per week and automatically extracts key statements from them that are "outcome centric." That is, the article must state some specific observation, technical finding, result, effect or conclusion about what medication or biological agent produced the new clinical outcome of merit.
Pharmaceutical professionals, doctors and patients can subscribe without charge to the CureHunter Rss feeds and select to track: Pharma manufacturer and specific products, all drugs with breaking news, only new scientific findings on their specific disease, news of new therapies, or all of the above.
CureHunter's high precision data extraction system keeps the information content in its feeds highly quality controlled and focused on usable results rather than general news, chat or information. The feed outputs are also quantified and weighted for clinical utility so they can be input into the main CureHunter analytic engine and become part of the machine's own memory of "what works" as originally published in close to 18 million research articles.
In this way, the CureHunter AI Discovery Engine continues to learn daily-like any good scientist--and modifies its "machine 2nd opinion" of best treatment options that is presented in seconds on every doctor's screen. The processed feed data also become part of CureHunter's Network Graph Theory models for drug discovery and automatic re-targeting and purposing of existing medications. If for example, a new biomarker is cited in the feed as correlating highly with a cancer, that data point will be retrieved and evaluated with all cancer markers when a patient or researcher is studying the specific illness or therapy for it.
Similarly, if a new medication or biological agent has been shown to achieve improved disease remission rates, that data will be captured and integrated into the system's knowledge of all medications that have shown clinical efficacy. The data will also automatically be correlated with related diseases and agents that share functional clinical properties, mechanisms of action, or pathogenic pathways.
Because the CureHunter Engine has been trained to seek "clinical effect centricity" across all diseases drugs and agents indexed since 1949, the machine can often discover relationships very quickly that historically have taken many years for human observers to realize and put to clinical use in new drug discovery or available treatments.
Through the CureHunter machine's ability to sum all we know toward clinical efficacy, the company hopes to support the FDA's Critical Path Program goals and their drive to speed up both new cure discovery and safety analyses that are now such powerful national health care priorities.
With Microsoft Windows Live Mail, Microsoft HealthVault, Internet Explorer, Safari, FireFox or other modern browsers, users can choose with a mouse click to have the particular CureHunter RSS News Feeds they wish by selecting research on their particular Medications, Disease, or Related Therapies or all three. Industry analysts can also select and track only those new outcomes achieved by specific pharmaceutical companies and even individual products.
The benefits of using the CureHunter intelligent news reader system are quite powerful, especially for patients and families hoping for breakthroughs on serious illness. A check of the morning's email might just alert them to very hopeful, promising or immediately usable new results they should discuss with their physicians.
At the same time our overworked physicians can be kept literally up to date as much as 4 months in advance of new journal research formal publication. Researchers can thoroughly evaluate prior art when preparing publications on their own preemptive work. Pharma marketers and stock analysts can also be automatically advised of competitive product and scientific advances mentioning their key meds in outcome centric papers. Health information sites and broadcasters with staff experts in medicine and pharmacy can also be kept very current by subscribing to CureHunter RSS feeds.
For more information or to start receiving new research, visit the company's web site, search a disease on the home page query field, and then select RSS feed icon at the top right hand column of the next page displayed.
URLS:
www.curehunter.com
Patients, doctors, scientists search Disease Name first on home page Rss will appear on page two with supporting information
Pharmaceutical Company and Product specific feeds: http://www.curehunter.com/public/fdaFirmSearch.do
Visual Medical Dictionary for medical and nursing students:
http://www.curehunter.com/public/dictionary.do
MOBILE PDA-Cell Phone Version:
http://www.curehunter.com/m/showTopPage.do
Partners and investors please use contact form at the site:
http://www.curehunter.com/public/contactForm.do
Corporate Background:
CureHunter is an Oregon Corporation founded in 2003, for the purpose of building an advanced artificial intelligence machine that uses massive biomedical knowledge bases to compute new cures for human disease. System access is licensed worldwide to doctors, scientists, and patients for the purposes of improving positive patient outcome rates, advancing our research knowledge, and enabling the practice of Evidence-Based Medicine in Real Clinical Time. Approximately 80,000 visitors per month ask CureHunter for its "Machine 2nd Opinion" of the optimal medication to treat specific illnesses.
The company has offices in Tokyo, Japan and Headquarters in Portland, Oregon, USA.
Contact:
CureHunter, Inc., Portland, Oregon
May 21, 2008 - 10:00 AM - PDT - USA
Judge Schonfeld, CEO - judge@curehunter.com or 503.246.6489
###
|
|
|
The American Lung Association of Illinois-Greater Chicago
Hosts 8th Annual Lung Walk Kickoff Luncheon
